VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

May 11, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-05-09

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-09	Common Stock	M	3314	$15.87	Acquired	636209	Direct
2012-05-09	Common Stock	S	2713	$60.59	Disposed	633496	Direct
2012-05-09	Common Stock	S	601	$61.31	Disposed	632895	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-05-09	Stock Option	$15.87	M	3314	Disposed	2012-07-21	Common Stock (3314)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	300000	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $60.59 (range $60.02 to $60.99).

F3: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $61.31 (range $61.04 to $61.90).

F5: Common stock held in grantor retained annuity trusts.

F6: Fully vested.